Advancing Care, Together
Semaglutide and tirzepatide offer remarkable health benefits that extend well beyond the scale. Explore the clinical evidence behind GLP-1 therapy.
Tirzepatide significantly reduced the risk of cardiovascular death or worsening heart failure events, along with improvements in health-related quality of life, functional capacity, and exercise tolerance.
Read Study →
Semaglutide helps improve liver health in people with MASH — a serious form of fatty liver disease — by reducing inflammation and liver damage.
Read Study →
Semaglutide helped slow the progression of chronic kidney disease in diabetic patients by improving blood sugar control and reducing high blood pressure and inflammation.
Read Study →
Semaglutide is associated with a reduced risk of developing Alzheimer's disease in patients with type 2 diabetes and may have neuroprotective effects.
Read Study →
In two large trials, tirzepatide produced a significant reduction in apnea-hypopnea index events, with patients also losing more weight, experiencing lower blood pressure, and reporting better sleep quality. Zepbound is now FDA-approved for OSA.
Read Study →
Three years of tirzepatide in individuals with obesity and prediabetes resulted in substantial, sustained weight reduction and a significantly lower risk of progression to type 2 diabetes.
Read Study →
A review of 52 studies found that GLP-1 medications — the same ones used for weight loss — may also help reduce inflammation and improve overall health in people living with rheumatoid arthritis and psoriatic arthritis.
Read Study →